Cariporide (HOE642) attenuates lactic acidosis induced pulmonary vein arrhythmogenesis.
OBJECTIVE
Lactic acidosis causes atrial fibrillation (AF), and pulmonary veins (PVs) are the most important focus for the generation of AF. Cariporide (HOE642), a Na(+)/H(+) blocker, can prevent atrial tachycardia-induced electrical remodeling. The purpose of this study was to investigate whether cariporide can prevent lactic acidosis-induced PV arrhythmogenesis.


METHODS
Conventional microelectrodes were used to record the action potentials (APs) before and after the administration of lactic acid (10 and 20 mM) in the absence and presence of cariporide (10 microM) pretreatment in isolated rabbit PV and atrial tissue preparations.


RESULTS
Lactic acidosis of 10 mM (pH 7.0+/-0.1) and 20 mM (pH 6.7+/-0.1) reduced PV (n=6) spontaneous rates from 2.5+/-0.3 to 1.6+/-0.4 (by 36+/-1%) and 1.1+/-0.4 Hz (by 56+/-2%), respectively, but lactic acidosis (10 and 20 mM) induced 12 episodes (3.9+/-0.2 Hz) and 23 episodes (4.0+/-0.3 Hz) of non-sustained burst firings in 4 PV specimens. Lactic acidosis (10 and 20 mM) decreased the AP amplitude (APA) and velocity of depolarization (Vmax), but increased the resting membrane potential (RMP), AP duration, and strength-response interval (SRI) in the PV and atrium. In the presence of cariporide (10 microM), lactic acidosis (10 and 20 mM) only reduced PV spontaneous rates from 2.4+/-0.2 to 1.8+/-0.4 (by 25+/-1%) and 1.6+/-0.4 Hz (by 33+/-1%), respectively, and prevented lactic acidosis-induced PV burst firings. Cariporide also reduced the effects of lactic acidosis on the RMP, AP duration, APA, Vmax, and SRI.


CONCLUSIONS
Lactic acidosis has significant arrhythmogenic effects on PVs, which may be attenuated by Na(+)/H(+) blockers.
Udyavar
Ameya R
AR
National Yang-Ming University, School of Medicine; Division of Cardiology and Cardiovascular Research Center, Veterans General Hospital-Taipei, Taipei, Taiwan.
Chen
Yao-Chang
YC
Cheng
Chen-Chuan
CC
Higa
Satoshi
S
Chen
Yi-Jen
YJ
Chen
Shih-Ann
SA
D000140:Acidosis, Lactic / Q000209:etiology / Q000517:prevention & control*; D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000503:physiopathology* / Q000517:prevention & control*; D004558:Electric Stimulation; D004594:Electrophysiology; D006146:Guanidines / Q000494:pharmacology*; D006325:Heart Atria / Q000187:drug effects; D066298:In Vitro Techniques; D019344:Lactic Acid / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects; D011667:Pulmonary Veins / Q000503:physiopathology*; D011817:Rabbits; D013450:Sulfones / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; D006146:Guanidines; D013450:Sulfones; D019344:Lactic Acid; C093373:cariporide